TY1B-DR4 Antibody

What is DR4 and what is its role in cancer biology?

DR4 (Death Receptor 4), also known as TRAIL-R1 or CD261, is a type I transmembrane protein that functions as a receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). It belongs to the tumor necrosis factor receptor superfamily (TNFRSF10A) and is expressed in most human tissues, particularly in the spleen, peripheral blood leukocytes, and thymus, as well as in various tumor-derived cell lines .

DR4, similar to other death receptors like Fas and TNFR1, mediates apoptosis and NF-κB activation in many cells and tissues. When TRAIL binds to DR4, it triggers a signaling cascade that leads to programmed cell death. This pathway plays a crucial role in normal cellular differentiation and development but has gained significant attention in cancer biology due to its potential to selectively induce apoptosis in cancer cells while largely sparing normal tissues .

DR4 and its related receptor DR5 have been established as promising targets for cancer treatment. Therapeutics targeting these receptors have shown effectiveness in killing many types of tumors and can synergize with traditional therapies to overcome resistance to conventional treatments .

How do DR4-specific antibodies differ from recombinant TRAIL in cancer research?

DR4-specific antibodies and recombinant TRAIL (rTRAIL) differ in several important ways that impact their utility in cancer research:

• Specificity: DR4 antibodies specifically target only the DR4 receptor, while rTRAIL can bind to both DR4 and DR5 receptors, as well as decoy receptors that do not induce apoptosis .

• Pharmacokinetics: Human monoclonal antibodies targeting DR4 have a long half-life (approximately 20 days for IgG1) compared to rTRAIL, which has a shorter circulation time. This property makes antibodies potentially more suitable for therapeutic applications requiring sustained activity .

• Immunogenicity: Human monoclonal antibodies tend to have low immunogenicity potential compared to recombinant proteins, which can be advantageous for therapeutic applications .

• Mechanism of Action: While both DR4 antibodies and rTRAIL induce apoptosis, the mechanism differs slightly. rTRAIL forms homotrimers that bind and trimerize DR4 receptors, whereas agonistic antibodies like m921 can bind to DR4 and induce signaling through mechanisms that may involve receptor clustering .

It remains unclear whether rTRAIL or agonistic antibodies will prove more efficacious in humans, and preclinical and clinical studies with both types of candidate therapeutics are ongoing .

What are the key characteristics to consider when selecting a DR4 antibody for research?

When selecting a DR4 antibody for research applications, researchers should consider several key characteristics:

• Epitope specificity: Determine whether the antibody recognizes the extracellular domain of DR4 and whether it competes with TRAIL for binding. Antibodies like m921 and m922 compete with rTRAIL for binding to DR4, suggesting they bind to epitopes that overlap with the TRAIL binding site .

• Recognition of native DR4: Some antibodies may bind well to recombinant DR4 but fail to recognize native cell surface-associated DR4. For example, while both m921 and m922 bind with similar high avidity to recombinant DR4, only m921 recognizes cell surface-associated DR4 .

• Agonistic activity: Determine whether the antibody has agonistic properties that can activate the DR4 pathway and induce apoptosis. Agonistic antibodies like m921 can inhibit the growth of DR4-expressing cancer cells .

• Specificity for DR4 versus DR5: Ensure the antibody does not cross-react with DR5 or other related receptors. Both m921 and m922 bind specifically to DR4 and do not bind to DR5 even at high concentrations .

• Binding affinity: Consider the binding avidity of the antibody. High-affinity antibodies (EC50 in the nM range or better) are generally preferable for most applications .

• Application compatibility: Verify that the antibody is suitable for your intended applications (e.g., flow cytometry, Western blot, immunoprecipitation, functional blocking) .

• Endotoxin levels: For functional studies, ensure the antibody has low endotoxin levels (e.g., less than 0.01 EU/μg) to avoid nonspecific effects .

How can DR4 antibodies be used to distinguish between DR4 and DR5-mediated apoptosis?

Distinguishing between DR4 and DR5-mediated apoptosis is crucial for understanding the specific contributions of each receptor in different tumor types. DR4-specific antibodies provide a valuable tool for this purpose:

• Selective activation: DR4-specific antibodies like m921 can selectively activate DR4 without engaging DR5, allowing researchers to isolate DR4-specific effects. This selectivity is evidenced by m921's ability to bind specifically to DR4 without cross-reactivity to DR5, even at high concentrations (1,000 nM) .

• Comparative studies: By using DR4-specific antibodies alongside DR5-specific antibodies in parallel experiments, researchers can compare the relative contributions of each receptor pathway. The inhibitory effect on cell growth observed with m921 on ST486 cells demonstrates the specific activation of DR4-mediated pathways .

• Receptor-specific knockdown validation: To confirm specificity, researchers can combine DR4 antibody treatment with siRNA knockdown of either DR4 or DR5. If the effects of the DR4 antibody are maintained after DR5 knockdown but abolished after DR4 knockdown, this confirms DR4-specific activity.

• Cell line selection: Using cell lines with differential expression of DR4 and DR5 can help elucidate receptor-specific effects. For instance, m921 inhibited the growth of DR4-positive ST486 cells but did not affect DR4-negative MCF-7 cells, confirming its specificity .

• Combination with receptor-specific inhibitors: Combining DR4 antibodies with specific inhibitors of downstream signaling components can help map the distinct signaling pathways activated by DR4 versus DR5.

These approaches enable researchers to delineate the specific contributions of DR4 and DR5 to apoptosis in various cells, which is essential for developing targeted therapeutic strategies and understanding resistance mechanisms .

What are the mechanisms of resistance to DR4 antibody-mediated apoptosis?

Resistance to DR4 antibody-mediated apoptosis can occur through several mechanisms, which researchers need to consider when designing experiments and interpreting results:

• Receptor expression levels: Low expression or absence of cell surface DR4 is a primary mechanism of resistance. For example, while m921 binds effectively to cell surface-associated DR4 on ST486 cells, it shows no effect on DR4-negative MCF-7 cells .

• Conformational differences: The conformation of cell surface-associated DR4 may differ from recombinant DR4, affecting antibody binding. This explains why m922, despite binding well to recombinant DR4, fails to recognize native DR4 on cell surfaces .

• Decoy receptors: Expression of decoy receptors (DcR1 and DcR2) that compete for TRAIL binding but lack functional death domains can inhibit DR4-mediated apoptosis, though this may be less relevant for DR4-specific antibodies.

• Anti-apoptotic proteins: Overexpression of anti-apoptotic proteins (e.g., c-FLIP, Bcl-2, Bcl-xL, IAPs) can block the apoptotic cascade downstream of DR4 activation.

• Defects in apoptotic machinery: Mutations or downregulation of caspases and other components of the apoptotic machinery can prevent execution of the death signal.

• Post-translational modifications: Glycosylation, palmitoylation, and other modifications of DR4 can affect receptor localization, clustering, and signaling capacity.

• Receptor internalization: Rapid internalization of DR4 following antibody binding may reduce efficacy in some cell types.

Understanding these resistance mechanisms is essential for developing strategies to overcome them, such as combining DR4 antibodies with sensitizing agents that target specific resistance mechanisms or identifying biomarkers that predict response to DR4-targeted therapies .

How can DR4 antibodies be utilized in combination with other cancer therapeutics?

DR4 antibodies show significant potential for combinatorial approaches in cancer treatment, as they can synergize with various conventional and targeted therapies:

• Combination with chemotherapeutics: DR4 antibodies can synergize with traditional therapies such as paclitaxel and carboplatin. Clinical studies investigating anti-TRAIL receptor agonistic antibodies in combination with these agents have shown potential for enhanced responses .

• Epigenetic modifiers: Combination with histone deacetylase inhibitors can enhance DR4 expression and sensitize resistant cells to DR4 antibody-mediated apoptosis .

• Radiation therapy: DR4 antibodies can sensitize cells to radiation-induced apoptosis, potentially allowing for lower radiation doses and reduced side effects.

• Targeted therapies: Combining DR4 antibodies with kinase inhibitors or other targeted agents can simultaneously block survival pathways while activating death pathways.

• Immune checkpoint inhibitors: DR4 antibodies could potentially complement immune checkpoint blockade by directly inducing tumor cell death while immune checkpoint inhibitors enhance T cell-mediated killing.

• Other death receptor agonists: Using DR4 antibodies alongside DR5-targeting agents might provide more comprehensive coverage against heterogeneous tumors expressing varying levels of each receptor.

• CAR-T cell approaches: Universal CAR systems, such as the Fabrack-CAR approach, could be combined with DR4 antibodies to enhance targeting specificity and efficacy .

The rationale for these combinations is to overcome resistance mechanisms and exploit synergistic interactions. Clinical efficacy of such combinations cannot be fully determined until results from Phase 2 and 3 studies are completed, but the preliminary data suggest that combination therapies including anti-TRAIL receptor agonistic antibodies may provide improved clinical responses .

What are the optimal conditions for testing DR4 antibody-induced apoptosis in vitro?

To achieve reliable and reproducible results when testing DR4 antibody-induced apoptosis in vitro, researchers should consider the following optimal conditions:

• Cell line selection: Choose cell lines with confirmed DR4 expression, such as the Burkitt B-cell lymphoma cell line ST486, which has moderate levels of DR4 and is sensitive to DR4-targeting antibodies .

• Antibody concentration: For agonistic antibodies like m921, a dose-response curve should be established. Effective concentrations typically range from 10-500 nM, with growth inhibition observed in a dose-dependent manner .

• Incubation time: Optimal incubation times vary between cell lines but typically range from 24-72 hours to allow sufficient time for apoptosis induction and detection.

• Culture conditions: Maintain cells in complete growth medium with appropriate serum concentration (typically 10% FBS) and ensure optimal cell density at the start of treatment .

• Controls:

  • Positive control: Recombinant TRAIL (rTRAIL) at 5-10 nM typically induces significant apoptosis in sensitive cell lines

  • Negative control: Isotype-matched IgG at the same concentration as the test antibody

  • Untreated control: Cells in medium alone

• Detection methods: Combine multiple approaches to comprehensively assess apoptosis:

  • Cell viability assays (MTT, MTS, or ATP-based assays)

  • Annexin V/PI staining for early/late apoptosis

  • Caspase activation assays (caspase-8, -3, -7)

  • PARP cleavage detection by Western blot

• For blocking experiments: When using antibodies to block TRAIL-induced apoptosis, use antibody at 2-3 μg/mL in cultivation medium, with TRAIL at 20-200 ng/mL, adding the antibody 15 minutes before TRAIL addition .

• Verification of DR4 expression: Confirm DR4 expression levels on target cells before experiments using flow cytometry with validated antibodies that recognize native cell surface DR4 .

By following these guidelines, researchers can establish robust assays for evaluating DR4 antibody-induced apoptosis and compare efficacy across different antibody clones or treatment conditions.

How should DR4 antibody binding to cell surface receptors be validated?

Validating DR4 antibody binding to cell surface receptors is crucial to ensure experimental results accurately reflect DR4-specific effects. A comprehensive validation approach includes:

• Flow cytometry analysis: The primary method to confirm binding to native cell surface DR4. Using ST486 cells (which express moderate levels of DR4), researchers can compare binding of test antibodies to established DR4 antibodies. As demonstrated with m921, effective antibodies should produce a distinct shift in the flow cytometry profile similar to positive control antibodies at the same concentration .

• Comparison with recombinant protein binding: While both m921 and m922 bound similarly to recombinant DR4 in ELISA (EC50 ~10 nM), only m921 recognized cell surface DR4. This highlights the importance of validating surface binding even when in vitro binding to recombinant proteins is strong .

• Competitive binding assays: Perform competition assays with known DR4 ligands or antibodies. The ability of m921 and m922 to compete with rTRAIL in binding assays confirms that they recognize epitopes overlapping with the TRAIL binding site .

• DR4-negative cell controls: Include DR4-negative cell lines (e.g., MCF-7) as specificity controls. Absence of binding to these cells confirms that the observed binding to DR4-positive cells is specific .

• Epitope mapping: Compare binding with antibodies recognizing known epitopes. Testing against antibodies like SC8411 (epitope near N-terminus), SC52923 (amino acids 1-20), and rabbit polyclonal Ab 06-744 (amino acids 77-90) can help determine the binding region .

• Functional validation: Confirm that antibody binding correlates with functional effects. For m921, binding to cell surface DR4 corresponded with inhibition of ST486 cell growth, providing functional validation of its binding .

• DR4 knockdown/knockout validation: Use DR4 knockdown or knockout cells to confirm binding specificity. Reduction or elimination of binding in these cells provides strong evidence of specificity.

• Cross-reactivity testing: Test binding to related receptors, particularly DR5. Both m921 and m922 showed no binding to DR5 even at high concentrations (1,000 nM), confirming their specificity for DR4 .

By implementing these validation steps, researchers can confidently establish whether their DR4 antibodies recognize native cell surface receptors in a specific manner, which is essential for interpreting experimental results correctly.

What are the recommended protocols for immunoprecipitation using DR4 antibodies?

While the search results don't provide a specific immunoprecipitation (IP) protocol for DR4 antibodies, a standard protocol can be adapted based on general immunoprecipitation principles and the specific characteristics of DR4 as a membrane receptor. Here is a recommended protocol:

• Cell lysis preparation:

  • Harvest 1-2 × 10^7 cells expressing DR4 (e.g., ST486 cells )

  • Wash cells twice with ice-cold PBS

  • Lyse cells in 1 mL of IP lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40 or 1% Triton X-100, 0.5% sodium deoxycholate, with protease inhibitor cocktail)

  • Incubate on ice for 30 minutes with occasional mixing

  • Centrifuge at 12,000 × g for 15 minutes at 4°C

  • Transfer supernatant to a new tube

• Pre-clearing (optional but recommended):

  • Add 50 μL of Protein A/G agarose beads to the lysate

  • Incubate with gentle rotation for 1 hour at 4°C

  • Centrifuge at 1,000 × g for 5 minutes

  • Transfer supernatant to a new tube

• Immunoprecipitation:

  • Add 2-5 μg of DR4 antibody (e.g., m921 ) to the pre-cleared lysate

  • Incubate with gentle rotation overnight at 4°C

  • Add 50 μL of Protein A/G agarose beads

  • Incubate with gentle rotation for 4 hours at 4°C

  • Centrifuge at 1,000 × g for 5 minutes

  • Discard supernatant

• Washing:

  • Wash beads 4-5 times with 1 mL of wash buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% NP-40 or 0.1% Triton X-100)

  • For each wash, gently mix, centrifuge at 1,000 × g for 5 minutes, and discard supernatant

• Elution:

  • Add 50 μL of 2× SDS sample buffer to the beads

  • Heat at 95°C for 5 minutes

  • Centrifuge at 1,000 × g for 5 minutes

  • Collect supernatant containing the immunoprecipitated proteins

• Analysis:

  • Analyze samples by SDS-PAGE and Western blotting

  • For DR4 detection, use a different DR4 antibody recognizing a distinct epitope to avoid interference from the heavy and light chains of the IP antibody

• Controls:

  • Negative control: Use an isotype-matched control antibody

  • Input control: Load 5-10% of the pre-cleared lysate

  • DR4-negative cells: Include a cell line known not to express DR4 (e.g., MCF-7 )

• Special considerations for DR4:

  • As a membrane protein, DR4 may require careful optimization of detergent conditions

  • For studying DR4 complexes, consider using chemical crosslinkers before lysis

  • If studying TRAIL-induced complexes, pre-treat cells with TRAIL (20-200 ng/mL) before lysis

This protocol should be optimized for specific experimental conditions, cell types, and antibodies being used.

How can DR4 antibodies contribute to understanding TRAIL-resistance mechanisms?

DR4 antibodies serve as valuable tools for dissecting TRAIL-resistance mechanisms in cancer research:

• Receptor-specific effects: DR4-specific antibodies like m921 allow researchers to distinguish between DR4 and DR5-mediated effects, helping to determine whether resistance is receptor-specific or affects the entire TRAIL pathway .

• Epitope mapping: The differential binding of m921 and m922 to cell surface DR4 despite similar binding to recombinant DR4 suggests that conformational differences may play a role in resistance. By using antibodies that recognize different epitopes, researchers can identify conformational changes or post-translational modifications that affect receptor function .

• Combination studies: Testing DR4 antibodies in combination with sensitizing agents can reveal specific resistance mechanisms. For instance, enhanced effects when combined with histone deacetylase inhibitors may indicate epigenetic regulation of pathway components .

• Correlation with receptor expression: While m921 inhibited the growth of DR4-positive ST486 cells but had no effect on DR4-negative MCF-7 cells, the levels of DR4 and DR5 expression do not always directly correlate with susceptibility to TRAIL pathway therapeutics. This suggests that factors beyond receptor expression contribute to resistance .

• Signaling pathway analysis: By activating specifically through DR4, researchers can trace the signaling events downstream of receptor activation to identify points of dysfunction in resistant cells.

• In vivo models: Testing DR4 antibodies in animal models allows for investigation of resistance mechanisms in a more physiologically relevant context, accounting for factors like tumor microenvironment that may contribute to resistance .

• Patient-derived xenografts: DR4 antibodies can be used to screen patient-derived samples to correlate clinical resistance with specific molecular features, potentially identifying biomarkers of response.

These approaches collectively enable researchers to build a comprehensive understanding of resistance mechanisms, which is essential for developing strategies to overcome resistance and for patient stratification in clinical trials of TRAIL pathway therapeutics .

What are the emerging applications of DR4 antibodies in CAR-T cell therapy?

While the search results don't specifically address DR4 antibodies in CAR-T cell therapy, they do provide insights into how antibody-based approaches are evolving in the field, which can be applied to DR4 targeting:

• Universal CAR systems: Search result describes a universal Fabrack-CAR system where the antigen recognition domain is replaced with a meditope peptide, and meditope-enabled monoclonal antibodies (memAbs) define the specificity. This concept could potentially be applied using DR4 antibodies like m921 .

• Combination approaches: DR4 antibodies could be used in combination with CAR-T cells to enhance tumor cell killing through complementary mechanisms. While CAR-T cells directly kill tumor cells expressing their target antigen, DR4 antibodies could induce apoptosis in cells that might otherwise escape CAR-T cell recognition.

• Overcoming tumor heterogeneity: One limitation of current CAR-T cell therapy is tumor heterogeneity. The universal Fabrack-CAR approach described in allows for targeting multiple antigens by simply administering antibodies with different specificities. DR4 antibodies could be part of such a multi-targeting strategy .

• Controllable CAR-T activity: Universal CAR systems can improve the controllability of CAR effector function. By using DR4 antibodies as part of this system, researchers could potentially modulate the intensity and timing of CAR-T cell activity.

• Addressing resistance: Tumor cells often develop resistance to single-target therapies. Incorporating DR4 antibodies into CAR-T approaches could provide an additional mechanism of action that may help overcome resistance to either approach alone.

• Reducing off-tumor toxicity: By carefully selecting combinations of targets, including DR4, researchers might be able to enhance specificity for tumor cells while reducing toxicity to normal tissues.

These potential applications represent an exciting frontier in cancer immunotherapy, combining the direct cytotoxic effects of DR4 targeting with the power of engineered T cells .

What are the limitations of current DR4 antibodies and how might they be improved?

Current DR4 antibodies, while promising, face several limitations that researchers are working to overcome:

• Affinity limitations: As noted with m921, the affinity of some DR4 antibodies is not optimal. Researchers are actively working on improving antibody affinity through techniques like affinity maturation to enhance therapeutic potential .

• Epitope recognition challenges: The difference between m921 and m922 in recognizing cell surface DR4 despite similar binding to recombinant DR4 highlights the challenge of developing antibodies that effectively recognize native conformations. Improved screening strategies using cell-based selections could address this limitation .

• Potency as single agents: While DR4 antibodies show promise, their efficacy as monotherapies may be limited. Current research focuses on combination approaches to enhance their effectiveness .

• Specificity vs. cross-reactivity: Highly specific DR4 antibodies like m921 and m922 don't bind to DR5, which is advantageous for research purposes but may limit therapeutic efficacy against heterogeneous tumors. Developing antibodies that can selectively target both receptors or creating optimized combination approaches may be beneficial .

• Resistance mechanisms: Multiple resistance mechanisms can limit DR4 antibody efficacy. Ongoing research aims to develop antibodies that can overcome these mechanisms or identify biomarkers to predict response .

• Pharmacokinetics and tissue penetration: While antibodies generally have favorable half-lives, their large size can limit tissue penetration. Engineering smaller formats like single-chain variable fragments (scFvs) or nanobodies might improve tissue distribution.

• Fc-mediated effects: Current research is exploring how to optimize the Fc region of DR4 antibodies to enhance immune effector functions like antibody-dependent cellular cytotoxicity (ADCC) while maintaining direct apoptosis-inducing capabilities.

• Manufacturing challenges: Production of consistent, high-quality antibodies at scale remains a challenge that impacts research and clinical development.

Future improvements may include:

• Development of bispecific antibodies targeting both DR4 and DR5

• Engineering antibodies with enhanced agonistic activity through optimized clustering

• Creation of antibody-drug conjugates combining direct apoptosis induction with cytotoxic payload delivery

• Rational design of epitope targeting based on structural insights into DR4-TRAIL interactions

• Incorporation of DR4 antibodies into novel platforms like the universal CAR systems described in search result

These advancements could significantly enhance the research and therapeutic utility of DR4 antibodies .

What are common pitfalls in DR4 antibody-based experiments and how can they be avoided?

Researchers working with DR4 antibodies should be aware of several common pitfalls that can affect experimental outcomes:

• Antibody selection issues:

  • Pitfall: Using antibodies that bind recombinant DR4 but fail to recognize native cell surface DR4.

  • Solution: Validate antibody binding to cell surface DR4 by flow cytometry, as demonstrated with m921 and m922, where only m921 recognized native DR4 despite both binding to recombinant protein .

• Cell line variability:

  • Pitfall: Inconsistent results due to varying DR4 expression levels across cell lines or passages.

  • Solution: Regularly verify DR4 expression levels in your cell lines by flow cytometry and Western blot. Include positive controls (e.g., ST486) and negative controls (e.g., MCF-7) in experimental designs .

• Competition assay design:

  • Pitfall: Inadequate controls in competition assays leading to misinterpretation.

  • Solution: When testing competition between antibodies and rTRAIL, maintain constant antibody concentration (e.g., 10 nM) while varying rTRAIL concentration. Include proper controls for non-specific binding .

• ELISA versus cell-based assays:

  • Pitfall: Assuming ELISA results translate directly to cell-based systems.

  • Solution: Always confirm ELISA findings with cell-based assays, as demonstrated by the different behaviors of m921 and m922 in these two systems .

• Functional assessment errors:

  • Pitfall: Relying on a single method to assess apoptosis.

  • Solution: Use multiple complementary methods to evaluate apoptosis (e.g., cell viability, Annexin V/PI staining, caspase activation) to obtain a comprehensive assessment.

• Experimental timing:

  • Pitfall: Inappropriate timepoints for apoptosis detection.

  • Solution: Include multiple timepoints in initial experiments to determine optimal timing for your specific cell system.

• Antibody handling:

  • Pitfall: Loss of antibody activity due to improper handling.

  • Solution: Follow manufacturer recommendations for storage and handling. For functional applications, ensure low endotoxin levels (<0.01 EU/μg) .

• Blocking experiment design:

  • Pitfall: Inadequate blocking conditions when using DR4 antibodies to inhibit TRAIL effects.

  • Solution: Add the blocking antibody (2-3 μg/mL) at least 15 minutes before TRAIL addition (20-200 ng/mL) .

• Cross-reactivity concerns:

  • Pitfall: Interpreting DR4-specific effects when antibodies may cross-react with DR5.

  • Solution: Verify antibody specificity by testing binding to both DR4 and DR5 recombinant proteins in parallel .

• Reproducibility challenges:

  • Pitfall: Inconsistent results across experiments.

  • Solution: Standardize protocols, use the same antibody lots when possible, and include appropriate positive and negative controls in each experiment.

By anticipating these common pitfalls and implementing the suggested solutions, researchers can improve the reliability and reproducibility of their DR4 antibody-based experiments.

How can researchers optimize DR4 antibody concentration for different experimental applications?

Optimizing DR4 antibody concentration is crucial for achieving reliable and reproducible results across different experimental applications. Here are guidelines for various common applications:

• Flow Cytometry:

  • Starting point: Begin with 1-10 μg/mL (approximately 7-70 nM for IgG).

  • Optimization approach: Perform a titration experiment with serial dilutions (e.g., 20, 10, 5, 2.5, 1, 0.5 μg/mL).

  • Evaluation metric: Select the concentration that provides clear separation between positive signal and background while minimizing non-specific binding.

  • Example: In the evaluation of m921, researchers compared binding at the same concentration as a reference mouse mAb, which yielded similar shifts in flow cytometry profiles .

• ELISA:

  • Starting point: 1-50 nM range for initial binding curves.

  • Optimization approach: Generate a complete binding curve to determine EC50.

  • Evaluation metric: The optimal working concentration is typically 2-3 times the EC50 value.

  • Example: For m921 and m922, EC50 values of approximately 10 nM were observed in ELISA binding to DR4 .

• Competition ELISA:

  • Fixed antibody concentration: 10 nM (as used for m921 and m922).

  • Variable competitor: Test competing molecules (rTRAIL or other antibodies) at concentrations ranging from 0.8 to 500 nM.

  • Example: At rTRAIL concentrations below 40 nM, binding of m921 and m922 (at 10 nM) was not diminished .

• Functional apoptosis assays:

  • Concentration range: Test a wide range, typically 10-500 nM.

  • Optimization approach: Perform dose-response experiments with multiple concentrations.

  • Controls: Include rTRAIL (5 nM) as a positive control and isotype-matched IgG as a negative control.

  • Example: m921 showed dose-dependent inhibition of ST486 cell growth across a range of concentrations .

• Blocking experiments:

  • Recommended concentration: 2-3 μg/mL (approximately 13-20 nM for IgG).

  • TRAIL concentration: 20-200 ng/mL.

  • Timing: Add antibody 15 minutes before TRAIL addition.

  • Source: These specific recommendations come directly from functional application guidelines .

• Western blotting:

  • Starting point: 0.1-2 μg/mL for primary antibody.

  • Optimization: Test multiple dilutions and incubation times.

  • Considerations: The optimal concentration may vary depending on the expression level of DR4 in your samples and the sensitivity of your detection system.

• Immunoprecipitation:

  • Starting point: 2-5 μg of antibody per 1 mL of cell lysate (from 1-2 × 10^7 cells).

  • Optimization: May need to adjust based on DR4 expression levels and antibody affinity.

For all applications, remember that:

• Optimal concentrations may vary between different antibody clones

• Batch-to-batch variations may require re-optimization

• Include appropriate positive and negative controls

• Document optimized conditions carefully for reproducibility

By systematically optimizing antibody concentration for each application, researchers can maximize specific signal while minimizing background and non-specific binding.

How should researchers interpret conflicting results between in vitro and cell-based DR4 antibody experiments?

When researchers encounter conflicting results between in vitro assays (like ELISA) and cell-based experiments with DR4 antibodies, systematic analysis is essential for proper interpretation. The search results provide a perfect example of such a discrepancy with m921 and m922 antibodies :

• Analyze potential causes of discrepancy:

  a) Conformational differences: Cell surface DR4 may have a different conformation than recombinant DR4 used in ELISA. As observed with m921 and m922, both bound similarly to recombinant DR4, but only m921 recognized cell surface DR4 .

  b) Epitope accessibility: Some epitopes may be inaccessible in the native membrane environment due to:

  • Receptor clustering or oligomerization

  • Interaction with other membrane proteins

  • Post-translational modifications

  • Partial embedding in the membrane

  c) Binding kinetics differences: In vitro assays may not reflect the dynamic binding kinetics occurring at the cell surface.

  d) Technical factors:

  • Different detection methods between assays

  • Buffer conditions affecting antibody binding

  • Protein coating orientation in ELISA

• Resolution strategies:

  a) Epitope mapping: Determine the precise epitopes recognized by antibodies showing discrepant results. The search results show attempts to map epitopes using competition with antibodies targeting known regions (SC8411, SC52923, rabbit polyclonal Ab 06-744) .

  b) Multiple cell lines: Test antibody binding across multiple cell lines with varying DR4 expression levels. The differential effects of m921 on DR4-positive ST486 cells versus DR4-negative MCF-7 cells helped confirm specificity .

  c) Receptor mutagenesis: Create point mutations in DR4 to identify critical binding residues and compare effects in recombinant protein versus cell-based assays.

  d) Alternative binding assays: Use surface plasmon resonance or bio-layer interferometry with purified receptors in different contexts (detergent-solubilized, liposome-reconstituted).

• Interpretation framework:

  a) Prioritize cell-based results: Cell-based assays generally provide more physiologically relevant information. The ability of m921 to bind cell surface DR4 and inhibit cancer cell growth makes it more promising than m922 despite similar in vitro binding .

  b) Consider functional relevance: A functional readout (like inhibition of cell growth) is ultimately more important than binding alone. m921's ability to inhibit ST486 cell growth demonstrated its functional relevance despite discrepancies with in vitro binding .

  c) Evaluate impact on research goals: Determine which assay better predicts the outcome relevant to your research question. For therapeutic antibody development, cell-based assays should be given higher priority.

  d) Use discrepancies as research opportunities: The differences between m921 and m922 reveal important insights about DR4 biology and structure that merit further investigation .

• Reporting recommendations:

  a) Document all discrepancies transparently: Include all conflicting data in publications and reports.

  b) Propose testable hypotheses: Suggest potential mechanisms for observed discrepancies.

  c) Consider implications for field: Discuss how the discrepancies might impact interpretation of other studies and clinical development efforts.

The example of m921 and m922 demonstrates how carefully analyzing discrepancies between in vitro and cell-based results can lead to valuable insights about receptor biology and antibody mechanisms .